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Abstract
Eight novel 2-(2, 6-dioxopiperidin-3-yl)phthalimidine EM-12 dithiocarbamates 9 and 10, N-
substituted 3-(phthalimidin-2-yl)-2, 6-dioxopiperidines 11–14 and 3-substituted 2, 6-
dioxopiperidines 16 and 18 were synthesized as tumor necrosis factor-α (TNF-β) synthesis 
inhibitors. Synthesis involved utilization of a novel condensation approach, a one-pot reaction 
involving addition, iminium rearrangement and elimination, to generate the phthalimidine ring 
required for the creation of compounds 9–14. Agents were, thereafter, quantitatively assessed for 
their ability to suppress the synthesis on TNF-β in a lipopolysaccharide (LPS)-challenged mouse 
macrophage-like cellular screen, utilizing cultured RAW 264.7 cells. Whereas compounds 9, 14 
and 16 exhibited potent TNF-α lowering activity, reducing TNF-α by up to 48% at 30 μM, 
compounds 12, 17 and 18 presented moderate TNF-α inhibitory action. The TNF-α lowering 
properties of these analogues proved more potent than that of revlimid (3) and thalidomide (1). In 
particular, N-dithiophthalimidomethyl-3-(phthalimidin-2-yl)-2, 6-dioxopiperidine 14 not only 
possessed the greatest potency of the analogues to reduce TNF-α synthesis, but achieved this with 
minor cellular toxicity at 30 μM. The pharmacological focus of the presented compounds is 
towards the development of well-tolerated agents to ameliorate the neuroinflammation that is 
commonly associated with neurodegenerative disorders, epitomized by Alzheimer’s disease and 
Parkinson’s disease.
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1. Introduction
Inflammation of the central nervous system, neuroinflammation, is now recognized as a key 
feature of all neurodegenerative disorders that, with the progressively aging population, are 
becoming increasingly prominent.1 Alzheimer’s disease (AD) and Parkinson’s disease (PD) 
are prime examples of debilitating disorders that impact over 5 million and one million 
Americans, respectively. Neuroinflammation incorporates a wide spectrum of complex 
cellular responses that often contribute to the pathogenesis and can ultimately drive the 
progression of a neurological disorder.2a–c The normal adult brain possesses low or 
undetectable levels of peripheral inflammatory cell subtypes. In the mature brain a primary 
intrinsic immune-competent cell type is the microglial cell. In the normal, inactivated state 
microglial cells display a ramified morphology.2c However, during either chronic or acute 
neuroinflammation, microglia activation rapidly occurs that results in an alteration in 
morphology and a subsequent release of many inflammatory mediators.2a–c Key amongst 
these is the pro-inflammatory cytokine, tumor necrosis-alpha (TNF-α), a potent activator of 
the immune system that can induce immune cell activation leading to the rapid recruitment 
of neighboring resting microglia or astrocytes within the adjacent brain 
microenvironment.2b,c
Pharmacological interventions that are able to reset the fine and often lost balance between 
resting and activated glial cells could be of significant clinical benefit.2c TNF-α protein is a 
key candidate therapeutic target as - based on data from many clinical, cell biology and 
animal studies - abnormal regulation of this protein is strongly associated with an 
unregulated glial cell activity and resulting neuroinflammation.2b The identification of novel 
agents which can restore the normal function of activated CNS glial cells by means of 
reducing the pro-inflammatory effects of TNF-α protein within brain represent a viable 
mechanism of action for the management of clinical disease.2c
Thalidomide (1) (Figure 1) is effective in alleviating erythema nodosum leprosum associated 
with leprosy and aphthous ulcers in AIDS patients.3a–d Although the mechanism via which 
this drug ameliorates these inflammatory diseases remains to be fully elucidated, 
thalidomide is known to induce a wide range of immunomodulatory actions. Amongst this 
diversity of activities is a TNF-α lowering action, mediated by destabilizing TNF-α mRNA 
levels at the level of its 3′-untranslated region to reduce the rate of synthesis of TNF-α 
protein.4a,b As the close thalidomide analogue, lenalidomide (revlimid (3) (Figure 1)), 
likewise possesses TNF-α action,3c,d the backbone holds promise as a multi-template for 
development of biologically active compounds. In addition, as thalidomide (1) displays a 
moderate degree of lipophilicity (C log D value −0.83)6a that allows it access to the brain, 
analogues bearing equivalent physicochemical properties may provide promise in the 
treatment of neurodegenerative diseases exacerbated by neuroinflammation. Additionally, as 
the TNF-α activity of 1 is not particularly potent, requiring administration of high doses that 
are often both sedative and associated with adverse effects,5 the synthesis of novel and more 
effective TNF-α lowering agents is a worthy goal. In this regard, several N-substituted 3-
(phthalimidin-2-yl)-2, 6-dioxopiperidines and 3-substituted 2, 6-dioxopiperidines are 
described that demonstrate promising anti-TNF-α potency.
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2. Results and discussion
2.1. Chemistry
Prior studies have identified a number of thalidomide analogues with improved TNF-α 
lowering properties in models of cellular and CNS neuroinflammation. In this regard, 
compounds in Figure 1 have demonstrated encouraging results regarding anti-TNF-α 
potency associated with tolerable cellular toxicity.6a–d
N-substituted thalidomide derivatives have been reported with potent antitumor activities.7 
Indeed, several N-alkylated thalidomide analogues have been screened in cell culture and 
then further evaluated in animals, in which a higher antitumor activity than that of 
thalidomide was observed.8a–f In general, when a sulfur atom was introduced into the 
thalidomide pharmacophore, a more potent antitumor activity was detected.9 Up to now the 
biological properties of N-dithiocarbamate substituted 3-(phthalimidin-2-yl)-2, 6-
dioxopiperidines have not been reported. Based on our unpublished observations and a 
structural analysis of specific known compounds possessing TNF-α inhibitory activity, we 
generated two novel N-dithiocarbamate substituted 3-(phthalimidin-2-yl)-2, 6-
dioxopiperidines, 9 and 10, as likely TNF-α inhibitors (Scheme 1).
Compounds 11–14 were synthesized as shown in Scheme 1. The rationale underpinning the 
conception of these agents is based on green chemistry,10 whereby two potentially active 
agents may, under appropriate conditions, derive from a single compound; thereby providing 
a form of ‘medicinal economy’. Specifically, under physiological conditions, the use of a 
methylene linkage to connect two nitrogen atoms, as in 11–14, may permit the occurrence of 
simple metabolism to allow generation of the corresponding 2-(2, 6-dioxopiperidin-3-
yl)phthalimidine EM-12 (2) (Figure 1), glutarimide, dithioglutarimide, phthalimide or 
dithiophthalimide. Importantly, these latter agents all possess a degree of TNF-α lowering 
potency.6a Previously, we and others have demonstrated that 2-(2, 6-dioxopiperidin-3-
yl)phthalimidine EM-12 (2) generates TNF-α inhibitory activity with a low cellular 
toxicity6c,e and that dithiophthalimide is likewise active and well tolerated.6a As illustrated 
in Table 1, compound 14, containing such a methylene linkage that simultaneously connects 
the 2-(2, 6-dioxopiperidin-3-yl)phthalimidine EM-12 and dithiophthalimide moieties, 
proved to be the most potent TNF-α lowering candidate amongst the eleven analyzed 
compounds.
For the syntheses of compounds 9–14, we adopted our own novel condensation approach to 
allow formation of the phthalimidine ring. This one-pot reaction involved addition, 
rearrangement and elimination. A potential mechanism underpinning this is shown in Figure 
2. The process proved to be simple and the product yield was good (ranging from 52% to 
89%), thereby providing a shortcut for synthesis of 2-(2, 6-dioxopiperidin-3-
yl)phthalimidine EM-12 analogues. In chemistry more generally, such dehydration spanning 
a nitrogen atom to form a lactam is, likewise, interesting and has not previously been 
reported. By contrast, previously published synthetic routes to yield EM-12 are greater than 
a single step, as is evident from the work of Luzzio and colleagues6f where synthesis was 
achieved in 6 steps in a yield of 25%. Other reports describe the use of a radical inducing 
reagent or UV light. In our one pot reaction, however, synthesis is undertaken at room 
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temperature and a yield up to 80% is achievable, even if undertaken in neutral or weakly 
basic reaction mediums.
Consequent to the introduction of hetero-atoms, such as sulfur and nitrogen, into 
thalidomide that provided significant TNF-α inhibitory activity, we designed compound 16, 
in which the 1, 3-carbonyl groups of thalidomide are replaced by sulfonyl groups, and 
compounds 17a and 18, in which the 1, 3–dioxo and 1-oxo of thalidomide were substituted 
by imino groups, respectively (Scheme 2, Figure 3).
For the synthesis of 17a, as illustrated in Figure 3, the principal product is 17.6c This can be 
attributed to the presence of a 1, 3-H transfer, as depicted in Figure 3, under the reaction 
conditions indicated. Two primary amino groups may prove more advantageous to support 
the intramolecular elimination of ammonia. The condensation of reactants 3-
iminoisoindolinone and 15 normally afforded product 18, which has been confirmed by two 
correlative peaks of 3′-H/1-C and 3;-H/3-C in the (1H-detected) heteronuclear multiple-
bond correlation (HMBC) spectrum. Syntheses of compounds 19 and 20 proved 
straightforward using the methods defined in Scheme 2, and the yield of 20 proved to be 
high (93%).
2.2. TNF-α inhibitory activity
Inhibition of LPS-induced TNF-α production in RAW 264.7 cells, cell viability and 
computed lipophilicity (C log D value) of assessed compounds 9–14, 16–20 are shown in 
Table 1. The biological activities of the above analogues were compared to those of revlimid 
(3). In addition to thalidomide (1), 3 is a credible TNF-α inhibitor,11a,b and is both approved 
for and effective in the for treatment of multiple myeloma and specific myelodysplastic 
syndromes.12a–f Herein, compounds 9, 12, 14 and 16–18 possessed more potent TNF-α 
inhibitory activity than that of revlimid (3) as well as thalidomide (1) in our assay model, 
which has now been extensively characterized.6c Indeed, compounds 9, 14 and 16 not only 
showed the most potency as TNF-α inhibitors amongst all eleven assayed compounds 
(contrasting markedly with revlimid (3)) but appeared well tolerated, albeit 14 was 
associated with a mild decline in cell viability at 30 μM. Parenthetically, the TNF-α activity 
of compound 17, whose chemistry is reported for the first time herein, compares favorably 
to that reported by Tweedie et al.,6c (agent A10), demonstrating the consistency of the assay 
across time.
The C log D values of our analogues, interestingly, ranged from lipophilic (9: +1.39) to 
water-soluble (16: −1.75) (Table 1), suggesting that their potency as TNF-α inhibitors 
related more to their structural configuration rather than to a physicochemical characteristic, 
such as lipophilicity, that would be predicted to augment cellular uptake. Clearly, structural 
configuration together with physicochemical properties impact the ability of a compound to 
suitably orientate, dock and then appropriately interact with a required target, such as one 
regulating TNF-α protein synthesis, and are thereby fundamental to its TNF-α lowering 
effects. However, regulation of TNF-α synthesis by thalidomide (1) and analogues is not 
mediated via a classical receptor or enzyme-based interaction for which structure-activity 
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relations are generally available but, instead, appears to involve complex post-transcriptional 
regulatory actions mediated at the level of the 3′-UTR of TNF-α mRNA.4a,b
In general, mRNAs are amenable to several forms of post-transcriptional regulation, which 
include pre-mRNA splicing and maturation (3′polyadenylation and 5′ capping), mRNA 
nuclear export to the cytoplasm, appropriate sub-cytoplasmic localization, stabilization and 
translation.13a–c Two major kinds of trans acting factors that recognize specific cis elements 
(RNA sequences) within the target mRNA are involved in the regulation of these steps, 
RNA-binding proteins (RBPs) and microRNAs. For TNF-α gene expression, the role of 
RBPs has been widely explored, whereas the part of microRNAs remains to be more fully 
characterized.13c,d For inflammatory cytokines like TNF-α, in particular, but also for IL-2, 
IL-6 and interferon-γ, synthesis is tightly regulated at the level of mRNA stability, thereby 
permitting rapid responses to external stimuli, as occurs for LPS. The presence of adenylate-
uridylate-rich elements (AREs) within the 3′-UTR of TNF-α mRNA plays a primary role in 
post-transcriptional repression, targeting it for rapid degradation or inhibition of 
translation.13a,b p38 MAPK has been implicated as a major signaling cascade facilitating the 
stability of TNF-α via its 3′-UTR ARE cis elements, which have been shown to be mediated 
through interactions with RBPs.13a–d In particular, proteins such as HuR, whose 
translocation to the cytoplasm is potently induced by oxidative stress and other aberrant 
stimuli,13c have been associated with promoting transcript stabilization. Upon export to the 
cytoplasm, HuR binds and stabilizes ARE-containing transcripts and conveys them to 
translational machinery. Conversely, RNA-binding proteins such as tristetraprolin (TTP) and 
related proteins (e.g., butyrate response factor 1 and 2) have a major regulatory role in 
accelerating the degradation of bound mRNAs, albeit the precise mechanisms accounting for 
this degradation are incompletely understood but they include the action of several cellular 
structures known to breakdown labile mRNAs, the proteasome, exosome and RNA 
processing-body.13a–c
It widely accepted that LPS challenge of RAW 264.7 cells extends the half-life of TNF-α 
mRNA, allowing release of its translational repression. By contrast, administration of 
thalidomide (1) induces an increase in translational blockade and a shortening of the TNF-α 
mRNA half-life from 30 min to 17 min.4a,14a,b Although yet to be elucidated, interactions 
between thalidomide analogs and the binding of HUR as well as TTP related RBPs with 3′-
UTR cis elements likely underpins alterations in the rate of TNF-α synthesis. In this regard, 
small chemical inhibitors that disrupt HuR:ARE binding have been described.14c,d As yet, 
insufficient compounds have been assessed to provide structure-activity relations, but such a 
target, or a strengthening of TTP:ARE binding, represents a potential means via which 
thalidomide analogs may effectively regulate TNF-α protein levels.
These same properties of thalidomide analogues may or may not be vital for 
pharmacological interactions with other targets, such as nitric oxide,15a,b known to be 
regulated by thalidomide (1) and are a focus of current studies. In the event that the 
inhibitory activity of designed compounds proves ideal, in part or in whole, it not only 
provides a basis to manipulate TNF-α levels to define its pharmacological role in health and 
disease, but also affords structural information to allow investigation of the target and its 
regulatory elements.
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In this regard, these TNF-α lowering data are sufficiently promising to indicate that further 
study of the pharmacology and biology of these agents is warranted in models of 
neurodegenerative diseases where a component of the disease pathology is associated with 
neuroinflammation.
3. Conclusion
Novel 2-(2, 6-dioxopiperidin-3-yl)phthalimidine EM-12 dithiocarbamates 9 and 10, N-
substituted 3-(phthalimidin-2-yl)-2, 6-dioxopiperidines 11–14 and 3-substituted 2, 6-
dioxopiperidines 16 and 18 were designed, prepared and assessed for TNF-α lowering 
activity. Synthesis involved a novel condensation approach for the generation of analogues 
of 2-(2, 6-dioxopiperidin-3-yl)phthalimidine EM-12 (2). In addition to N-substituted 3-
(phthalimidin-2-yl)-2, 6-dioxopiperidines 14 and 9, 3-(o-benzenedisulfonimid-2-yl)-2, 6-
dioxopiperidine 16 proved to be a potent anti-TNF-α candidate agent. These novel 
compounds thereby provide potential promise as immunomodulatory drugs candidates 
whose biological and pharmacological actions warrant further assessment in animal models 
of inflammatory disorders. Particularly relevant would be a neuroinflammatory focus, as 
invariably occurs in neurodegenerative conditions, exemplified by Alzheimer’s disease and 
Parkinson’s disease.
4. Experimentals
4.1. Chemistry
Melting points (uncorrected) were measured with a Fisher-Johns apparatus. 1H NMR, 
and 13C NMR were recorded on a Bruker (Bellevica, MA) AC-300 spectrometer. MS (m/z) 
data were measured on an Agilent 5973 GC-MS (CI). Elemental analyses were performed 
by Atlantic Microlab, Inc. (Norcross, GA). All reactions involving non-aqueous solutions 
were performed under an inert atmosphere.
4.1.1. 1-Hydroxymethyl-3-(tert-butoxycarbonylamino)-2, 6-dioxopiperidine (5)
—A mixture of 3-(tert-butoxycarbonylamino)-2, 6-dioxopiperidine 4 (7.10 g, 31.1 mmol) 
and formaldehyde (37% solution in water, 37.2 ml) was refluxed under an atmosphere of 
nitrogen for 0.5 h. After cooling, isolated precipitate was recrystallized with acetone to 
afford product 5 (5.85 g, 72.9 %) as white crystals: mp 216.5–217.5 °C; 1H NMR (DMSO-
d6) δ 7.20 (d, J = 6.0 Hz, 1H, NH), 6.04 (t, J = 10.5 Hz, 1H, OH), 5.05–4.92 (m, 2H, 
CH2OH), 4.38–4.22 (m, 1H, C3-H), 2.89–2.59 (m, 2H), 1.99–1.83 (m, 2H) and 1.41 (s, 9H, 
CH3) ppm; 13C NMR (DMSO-d6) δ 172.1, 171.9, 155.8, 78.5, 62.7, 51.3, 31.6, 28.5 and 
23.6 ppm; MS (CI/CH4), m/z 257 (M-1).
4.1.2. 1-Chloromethyl-3-(tert-butoxycarbonylamino)-2, 6-dioxopiperidine (6)—
Thionyl chloride (7.35 g, 61.8 mmole) was dropwise added to a solution of compound 5 
(5.83 g, 22.6 mmole) in DMF (17 mL) at 0 °C. The mixture was reacted for 1 h maintained 
at the same temperature. Thereafter, it was poured onto ice (60 g). Precipitate was isolated 
and was washed with ice water to pH 7 ca. The crude product was recrystallized with 
acetone to afford 6 (5.7 g, 90.5 %) as a white solid: mp 134.0–135.0 °C; 1H NMR (DMSO-
d6) δ 7.31 (d, J = 6.1 Hz, 1H, NH), 5.49 (s, 2H, CH2Cl), 4.58–4.30 (m, 1H, C3-H), 3.08–
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2.67 (m, 2H), 2.10–1.87 (m, 2H) and 1.48 (s, 9H, CH3) ppm; 13C NMR (DMSO-d6) δ 
171.5, 171.1, 155.8, 78.7, 51.3, 48.5, 31.4, 28.5 and 23.3 ppm; MS (CI/CH4), m/z 276 (M+).
4.1.3. 3-Amino-1-chloromethyl-2, 6-dioxopiperidine trifluoroacetate (7)—
Trifluoroacetic acid (28.4 mL) was dropwise added into a solution of compound 6 (4.0 g, 
14.5 mmol) in dichloromethane (274 mL) at room temperature. The mixture was reacted for 
22.5 h under an atmosphere of nitrogen at the same temperature. Thereafter, it was 
concentrated and precipitated with ether. Isolated solid was dried overnight to afford product 
7 (4.05 g, 96.2 %) as a purplish salt; 1H NMR (DMSO-d6) δ 8.80 (s, 3H, NH3+), 5.56 and 
5.50 (AB system, J = 9.2 Hz, 2H, CH2Cl), 4.51–4.28 (m, 1H, C3-H), 3.01–2.71 (m, 2H) and 
2.31–1.90 (m, 2H) ppm; 13C NMR (DMSO-d6) δ 170.2, 169.2, 159.0, 158.5, 49.9, 48.1, 
30.6 and 21.3 ppm; MS (CI/CH4), m/z 288 (M-2).
4.1.4. 2-(1-Chloromethyl-2, 6-dioxopiperidin-3-yl)phthalimidine (8)—A mixture of 
phthaldialdehyde (2.74 g, 20.4 mmol) and compound 7 (5.94 g, 20.4 mmol) in THF (1.7 L) 
was stirred under an atmosphere of nitrogen at room temperature for 71 h. Thereafter, 
solvent was removed, and the crude product was purified with chromatography on silica gel 
(CH3CN/CH2Cl2 = 1/4) to afford product 8 (3.1 g, 51.7 %) as a white solid: mp 180.5–
181.0 °C; 1H NMR (CDCl3) δ 7.94–7.43 (m, 4H, Ar-H), 5.59 and 5.51 (AB system, J = 8.1 
Hz, 2H, CH2Cl), 5.30–5.19 (m, 1H, C3′-H), 4.50 and 4.36 (AB system, J = 16.5 Hz, 2H, 
C3-H), 3.15–2.85 (m, 2H) and 2.46–2.13 (m, 2H) ppm; 13C NMR (CDCl3) δ 169.4, 169.3, 
168.6, 141.4, 132.1, 131.3, 128.3, 124.2, 122.9, 52.5, 47.2, 47.1, 31.9 and 22.3 ppm; MS 
(CI/CH4), m/z 294 (M+2). Anal. Calcd for C14H13ClN2O3: C, 57.44; H, 4.48; N, 9.57. 
Found: C, 57.37; H, 4.46; N, 9.17.
4.1.5. [3-(1-Oxo-1, 3-dihydro-1H-isoindol-2-yl)-2, 6-dioxopiperidin-1-yl]methyl 
cyclohexyldithiocarbamate (9)—A mixture of compound 8 (37.0 mg, 0.126 mmol), 
carbon disulfide (19.2 mg, 0.252 mmol) and cyclohexylamine (25.1 mg, 0.253 mmol) in 
acetonitrile (7 mL) was reacted for 42.5 h under an atmosphere of nitrogen at room 
temperature. After removing solvent, the residues were separated with chromatography on 
silica gel (MeOH/CH2Cl2 = 1/20) to afford product 9 (36.0 mg, 66.7%) as a yellow crystals: 
mp 128.0–129.0 °C; 1H NMR (CDCl3) δ 8.75 (s, 1H, NH), 7.95–7.38 (m, 4H, Ar-H), 5.31–
5.01 (m, 3H, C3′-H and CH2S), 4.49–4.25 (m, 2H, C3-H) and 3.14–1.05 (m, 15H, C5,4-H 
and cyclohex-H) ppm; 13C NMR (CDCl3) δ 191.2, 171.3, 170.2, 169.3, 141.3, 132.1, 131.3, 
128.3, 124.2, 122.9, 55.8, 52.6, 47.4, 43.3, 31.8, 31.4, 25.3, 24.7 and 22.3 ppm; MS (CI/
CH4), m/z 432 (MH+). Anal. Calcd for C21H25N3O3S2: C, 58.44; H, 5.84; N, 9.74. Found: 
C, 58.05; H, 5.88; N, 9.47.
4.1.6. [3-(1-Oxo-1, 3-dihydro-1H-isoindol-2-yl)-2, 6-dioxopiperidin-1-yl]methyl 
piperidin-1-carbodithioate (10)—A mixture of compound 8 (33.0 mg, 0.113 mmol), 
carbon disulfide (17.2 mg, 0.226 mmol) and piperidine (19.2 mg, 0.225 mmol) in 
acetonitrile (6 mL) was reacted for 46.0 h under an atmosphere of nitrogen at room 
temperature. After removing solvent, the residues were separated with chromatography on 
silica gel (MeOH/CH2Cl2 = 1/15) to afford product 10 (33.5 mg, 71.0 %) as a white powder: 
mp 180.0–181.5 °C; 1H NMR (CDCl3) δ 7.90–7.41 (m, 4H, Ar-H), 5.79 and 5.68 (AB 
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system, J = 14.5 Hz, 2H, CH2S), 5.29–5.18 (m, 1H, C3′-H), 4.49 and 4.30 (AB system, J = 
16.5 Hz, 2H, C3-H), 4.24 (s, br, 2H, pip-C2,6-H), 3.81 (s, br, 2H, pip-C2,6-H), 3.09–2.81 
(m, 2H), 2.41–2.11 (m, 2H) and 1.79–1.54 (m, 6H, pip-C3,4,5-H) ppm; 13C NMR (CDCl3) 
δ 192.7, 170.3, 169.2, 141.4, 131.9, 131.4, 128.1, 124.0, 122.8, 52.4, 51.6, 47.1, 46.4, 32.0, 
25.8, 24.1 and 22.5 ppm; MS (CI/CH4), m/z 258 (M-159). Anal. Calcd for C20H23N3O3S2: 
C, 57.53; H, 5.55; N, 10.06. Found: C, 57.80; H, 5.38; N, 9.95.
4.1.7. N-(1, 3-dioxopiperidin-2-yl)methyl-3-(1-oxo-1, 3-dihydro-1H-isoindol-2-
yl)-2, 6-dioxopiperidine (11)—A mixture of glutarimide (36.0 mg, 0.318 mmol) and 
potassium hydroxide (42 mg, 0.750 mmol) in acetonitrile (42 mL) was stirred for an hour at 
room temperature. Thereafter, compound 8 (93.0 mg, 0.318 mmol) was added to the reaction 
system and stirred for a further 17 h under an atmosphere of nitrogen at the same 
temperature. After removing solvent, the residues were separated with chromatography on 
silica gel (CH3CN/CH2Cl2 = 1/3) to afford product 11 (68.0 mg, 57.9 %) as a white solid: 
mp 216.5–217.0 °C; 1H NMR (CDCl3) δ 7.88 (d, J = 9.0 Hz, 1H, C7-H), 7.57 (d, J = 8.5 
Hz, 1H, C4-H), 7.46 (t, J = 9.0 Hz, 2H, C5,6-H), 5.85 (s, 2H, CH2N2), 5.19–5.10 (m, 1H, 
C3′-H), 4.52 and 4.35 (AB system, J = 16.5 Hz, 2H, C3-H), 3.08–1.81 (m, 10H, C5′,4′-H 
and glu-H) ppm; 13C NMR (CDCl3) δ 171.9, 170.3, 169.4, 169.3, 141.6, 132.0, 131.7, 
128.2, 124.1, 123.0, 52.8, 47.4, 45.0, 32.9, 32.2, 22.8 and 17.0 ppm; MS (CI/CH4), m/z 300 
(M-69). Anal. Calcd for C19H19N3O5H2O: C, 58.91; H, 5.46; N, 10.85. Found: C, 59.17; H, 
5.38; N, 10.61.
4.1.8. N-(1, 3-dithioxopiperidin-2-yl)methyl-3-(1-oxo-1, 3-dihydro-1H-isoindol-2-
yl)-2, 6-dioxopiperidine (12)—A mixture of dithioglutarimide (46.2 mg, 0.318 mmol), 
potassium hydroxide (42 mg, 0.750 mmol) and compound 8 (93.0 mg, 0.318 mmol) in 
acetonitrile (42 mL) was stirred for 16 h under an atmosphere of nitrogen at room 
temperature. After removing solvent, the residues were separated with chromatography on 
silica gel (CH3CN/CH2Cl2 = 1/3) to afford product 12 (33.0 mg, 25.8 %) as a yellow solid: 
mp 218.0–220.0 °C; 1H NMR (CDCl3) δ 7.91–7.43 (m, 4H, Ar-H), 5.22–5.12 (m, 1H, C3′-
H), 5.07 and 4.94 (AB system, J = 10.1 Hz, 2H, CH2N2), 4.50 and 4.39 (AB system, J = 
16.5 Hz, 2H, C3-H), 3.09–1.89 (m, 10H, C5′,4′-H and thioglu-H) ppm; 13C NMR (CDCl3) 
δ 201.7, 170.9, 169.8, 169.5, 141.6, 132.2, 131.6, 128.4, 124.4, 123.1, 53.1, 48.1, 43.6, 37.6, 
32.0, 22.6 and 21.2 ppm; MS (CI/CH4), m/z 404 (M+3). Anal. Calcd for 
C19H19N3O3S2H2O: C, 54.40; H, 5.04; N, 10.01. Found: 54.08; H, 4.42; N, 9.48.
4.1.9. N-Phthalimidomethyl-3-(1-oxo-1, 3-dihydro-1H-isoindol-2-yl)-2, 6-
dioxopiperidine (13)—A mixture of phthalimide (46.8 mg, 0.318 mmol) and potassium 
hydroxide (42 mg, 0.750 mmol) in acetonitrile (42 mL) was stirred for an hour at room 
temperature. Thereafter, compound 8 (93.0 mg, 0.318 mmol) was added to the reaction 
system and stirred for another 17 h under an atmosphere of nitrogen at the same 
temperature. After removing solvent, the residues were separated with chromatography on 
silica gel (CH3CN/CH2Cl2 = 1/3) to afford product 13 (67.0 mg, 52.2 %) as a white solid: 
mp 209.5–210.5 °C; 1H NMR (CDCl3) δ 7.95–7.40 (m, 8H, Ar-H), 5.83 and 5.72 (AB 
system, J = 13.5 Hz, 2H, CH2N2), 5.39–5.23 (m, 1H, C3′-H), 4.54 and 4.34 (AB system, J = 
16.6 Hz, 2H, C3-H), 3.10–2.82 (m, 2H) and 2.46–2.11 (m, 2H) ppm; 13C NMR (CDCl3) δ 
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170.3, 169.6, 169.3, 167.0, 141.7, 134.3, 132.0, 131.7, 131.6, 128.2, 124.2, 123.6, 123.0, 
52.5, 47.1, 43.6, 32.1 and 22.7 ppm; MS (CI/CH4), m/z 390 (M-13). Anal. Calcd for 
C22H17N3O5: C, 65.50; H, 4.25; N, 10.42. Found: C, 65.32; H, 4.12; N, 10.21.
4.1.10. N-Dithiophthalimidomethyl-3-(1-oxo-1, 3-dihydro-1H-isoindol-2-yl)-2, 6-
dioxopiperidine (14)—A mixture of dithiophthalimide (57.0 mg, 0.318 mmol) and 
potassium hydroxide (42 mg, 0.750 mmol) in acetonitrile (42 mL) was stirred for an hour at 
room temperature. Thereafter, compound 8 (93.0 mg, 0.318 mmol) was added to the reaction 
system and stirred for another 17 h under an atmosphere of nitrogen at the same 
temperature. After removing solvent, the residues were separated with chromatography on 
silica gel (CH3CN/CH2Cl2 = 1/3) to afford product 14 (17.0 mg, 12.3 %) as a yellow 
gum. 1H NMR (CDCl3) δ 7.98–7.39 (m, 8H, Ar-H), 6.47 (s, 2H, CH2N2), 5.31–5.19 (m, 
1H, C3′-H), 4.49 and 4.32 (AB system, J = 16.3 Hz, 2H, C3-H), 3.09–2.79 (m, 2H) and 
2.49–2.07 (m, 2H) ppm; 13C NMR (CDCl3) δ 197.0, 170.4, 169.3, 169.1, 141.5, 134.8, 
133.5, 132.0, 131.6, 128.2, 124.2, 123.6, 123.0, 52.5, 49.1, 47.1, 32.2 and 22.7 ppm; MS 
(CI/CH4), m/z 383 (M-52). Anal. Calcd for C22H17N3O3S21/3 H2O: C, 59.87; H, 4.03; N, 
9.52. Found: C, 59.91; H, 3.71; N, 9.17.
4.1.11. 3-(o-Benzenedisulfonimid-2-yl)-2, 6-dioxopiperidine (16)—A mixture of 1, 
2-benzenedisulfonyl dichloride (1.00 g, 3.63 mmol), 3-amino-2, 6-dioxopiperidine 
trifluoroacetate 15 (0.88 g, 3.63 mmol) and triethylamine (1.10 g, 10.87 mmol) in anhydrous 
THF (100 mL) was first reacted for 1.5 h at room temperature under an atmosphere of 
nitrogen, and, thereafter, it was refluxed for 24 h under an atmosphere of nitrogen. 
Following cooling, a grey crude product was filtered. This was recrystallized from hot 
acetone to provide product 16 (0.77 g, 64.2 %) as a purplish powder: mp 253 °C (dec.); 1H 
NMR (DMSO-d6) δ 11.08 (s, 1H, NH), 8.40–8.01 (m, 4H, Ar-H), 5.51–5.40 (m, 1H, C3′-
H), 2.96–2.51 (m, 2H) and 2.50–2.30 (m, 2H) ppm; 13C NMR (DMSO-d6) δ 172.5, 169.1, 
137.4, 135.8, 122.3, 59.0, 31.5 and 24.7 ppm; MS (CI/CH4), m/z 331 (MH+). Anal. Calcd 
for C11H10N2O6S2: C, 39.99; H, 3.05; N, 8.48. Found: C, 40.57; H, 3.22; N, 8.21.
4.1.12. 3-(1, 3-Diimino-1, 3-dihydro-2H-isoindol-1N-yl)-2, 6-dioxopiperidine (17)
—A mixture of 1, 3-diiminoisoindoline (0.50 g, 3.44 mmol), 3-amino-2, 6-dioxopiperidine 
trifluoroacetate 15 (0.83 g, 3.43 mmol) and triethylamine (0.95 g, 9.39 mmol) in THF (200 
mL) was refluxed for 98 h under an atmosphere of nitrogen. After cooling, a grey crude 
product was filtered. This was recrystallized from hot acetone to afford product 17 (0.67 g, 
76.1 %) as a gray powder: mp 246 °C (dec.); 1H NMR (DMSO-d6) δ 10.72 (s, 1H, CONH), 
8.51 and 8.39 (sh, 2H, CCNH and C=NH), 7.90–7.50 (m, 4H, Ar-H), 5.01 (t, J = 5.5 Hz, 1H, 
C3′-H), 2.61 (m, 2-H) and 2.04 (m, 2-H) ppm; 13C NMR (DMSO-d6) δ 173.8, 173.5, 170.6, 
168.5, 139.8, 136.1, 131.1, 130.3, 121.5, 121.0, 59.2, 30.3 and 26.3 ppm; MS (CI/CH4), m/z 
257 (MH+). Anal. Calcd for C13H12N4O2: C, 60.93; H, 4.72; N, 21.86. Found: C, 60.89; H, 
4.82; N, 21.58.
4.1.13. 3-(1-Oxo-3-imino-1, 3-dihydro-2H-isoindol-2-yl)-2, 6-dioxopiperidine 
(18)—A mixture of 3-iminoisoindolinone (0.50 g, 3.42 mmol), 3-amino-2, 6-
dioxopiperidine trifluoroacetate 15 (0.83 g, 3.43 mmol) and triethylamine (0.94 g, 9.29 
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mmol) in THF (200 mL) was refluxed for 72 h under an atmosphere of nitrogen. After 
removing solvent, crude product was recrystallized from hot acetone to afford product 18 
(0.38 g, 43.2 %) as a white powder: mp 267 °C (dec.); 1H NMR (DMSO-d6) δ 11.15, 10.90 
(2s, 2H, 2NH), 7.88–7.68 (m, 4H, Ar-H), 4.46 (t, J = 7.6 Hz, 1H, C3′-H), 2.71–2.59 (m, 2H) 
and 2.22–2.08 (m, 2H) ppm; 13C NMR (DMSO-d6) δ 173.4, 172.0, 169.2, 152.5, 136.6, 
133.9, 132.5, 131.5, 123.1, 122.3, 59.5, 30.4 and 26.1 ppm; MS (CI/CH4), m/z 257 (M+). 
Anal. Calcd for C13H11N3O3: C, 60.70; H, 4.31; N, 16.33. Found: C, 60.67; H, 4.38; N, 
16.20.
4.1.14. 3-(4-Aza-1, 3-dioxo-1, 3-dihydro-2H-isoindol-2-yl)-2, 6-dioxopiperidine 
(19)—A mixture of 2, 3-pyridinedicarboxylic anhydride (1.0 g, 6.71 mmol) and 3-amino-2, 
6-dioxopiperidine trifluoroacetate 15 (1.63 g, 6.73 mmol) in acetic acid (51 mL) was 
refluxed under an atmosphere of nitrogen for 7.5 h. After removing solvent, crude product 
was recrystallized from acetone to afford product 19 (0.18 g, 10.3 %) as white needle 
crystals: mp 266.0–267.5 °C; 1H NMR (CDCl3) δ 8.95 (s, br, 1H, C5-H), 8.13 (d, J = 9.3 
Hz, 1H, C7-H), 8.00 (s, 1H, NH), 7.61 (s, br, 1H, C6-H), 5.11–4.91 (m, 1H, C3′-H), 2.99–
2.65 (m, 3H) and 2.21–2.09 (m, 1H) ppm; 13C NMR (CDCl3) δ 170.2, 167.2, 165.2, 165.0, 
155.7, 151.3, 131.6, 127.7, 127.2, 49.6, 31.3 and 22.5 ppm; MS (CI/CH4), m/z 259 (M+). 
Anal. Calcd for C12H9N3O4: C, 55.60; H, 3.50; N, 16.21. Found: C, 55.03; H, 3.62; N, 
15.74.
4.1.15. 3-(5-Aza-1, 3-dioxo-1, 3-dihydro-2H-isoindol-2-yl)-2, 6-dioxopiperidine 
(20)—A mixture of 3, 4-pyridinedicarboxylic anhydride (1.0 g, 6.71 mmol) and 3-amino-2, 
6-dioxopiperidine trifluoroacetate 15 (1.63 g, 6.73 mmol) in acetic acid (51 mL) was 
refluxed under an atmosphere of nitrogen for 6.5 h. After removing solvent, crude product 
was recrystallized from acetone to afford product 20 (1.62 g, 93.1 %) as white crystals: mp 
234.0–235.5 °C; 1H NMR (DMSO-d6) δ 11.18 (s, 1H, NH), 9.29–9.10 (m, 2H, C4-H, C6-
H), 7.99 (d, J = 7.8 Hz, 1H, C7-H), 5.31–5.15 (m, 1H, C3′-H), 3.05–2.39 (m, 3H) and 2.19–
2.02 (m, 1H) ppm; 13C NMR (DMSO-d6) δ 173.0, 169.9, 166.8, 166.4, 156.7, 144.7, 139.1, 
125.7, 117.5, 49.6, 31.2 and 22.1 ppm; MS (CI/CH4), m/z 259 (M+). Anal. Calcd for 
C12H9N3O4: C, 55.60; H, 3.50; N, 16.21. Found: C, 55.65; H, 3.56; N, 15.99.
4.2. Biological assay
RAW 264.7 cells were cultured and treated with thalidomide analogues and LPS as has been 
previously described.6c In a manner similar to its use herein in cell culture, LPS has been 
found to elevate TNF-α levels in animals – both systemically as well as within the brain, and 
to be associated with neurodegenerative disease onset.16a,b The CellTiter 96 Aqueous One 
Solution Cell Proliferation Assay (Promega, Madison, WI) is a commercially used assay that 
is widely used to quantitatively determine cell proliferation, and this assay was utilized in 
our studies in line with the manufacturer’s guidelines. Changes in cellular health status can 
be determined by use of indirect measures related to the formation of a colored tetrazolium 
dye product that can be measured spectrophotometrically at 490 nm. An increase in 
absorbance at 490 nm is indicative of an increase in cell numbers and thus cell proliferation; 
and a decrease in absorbance is indicative of cell death. Data are expressed as a percentage 
change in Optical Densities (O.D.) compared to the appropriate control values. TNF-α 
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protein levels were measured in culture media by use of an ELISA specific for mouse TNF-
α protein (BioLegend MAX™ Mouse TNF-α ELISA Kit, BioLegend, San Diego, CA) and 
are expressed as a percentage change from the appropriate control.
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Figure 1. 
Known thalidomide, EM-12, revlimid and sulfur containing analogues possessing TNF-α 
action
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Figure 2. 
Possible Mechanism Forming Intermediate 8
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Figure 3. 
Possible Mechanism Forming Compound 17
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Scheme 1. 
Reagents and conditions: (i) Formaldehyde (37% solution in water), N2, reflux, 0.5 h; (ii) 
thionyl chloride, DMF, 0 °C, 1 h; (iii) trifluoroacetic acid, CH2Cl2, N2, rt, 22.5 h; (iv) 
phthaldialdehyde, THF, N2, rt, 71 h; (v) carbon disulfide, cyclohexylamine (for 9), 
piperidine (for 10), CH3CN, N2, rt, 42 to 46 h; (vi) glutarimide (for 11), dithioglutarimide 
(for 12), KOH, CH3CN, N2, rt, 16 to 18 h; (vii) phthalimide (for 13), dithiophthalimide (for 
14), KOH, CH3CN, N2,rt, 18 h.
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Scheme 2. 
Reagents and conditions: (i) 1,2-Benzenedisulfonyl dichloride, Et3N, THF, N2, reflux, 24 h; 
(ii) 1,3-diiminoisoindoline, Et3N, THF, N2, reflux, 98 h; (iii) 3-iminoisoindolinone, Et3N, 
THF, N2, reflux, 72 h; (iv) 2,3-pyridinedicarboxylic anhydride, AcOH, N2, reflux, 7.5 h; (v) 
3,4-pyridinedicarboxylic anhydride, AcOH, N2, reflux, 6.5 h.
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